Source · Prevention of Future Deaths

Aaron McCaffrey

Ref: 2017-0195 Date: 16 Jun 2017 Coroner: Rachel Galloway Area: Manchester (South) Responses identified: 0 / 1 View PDF

The lack of purchase limits for loperamide medication at retail stores enables bulk buying, increasing the risk of addiction and overdose.

Date 16 Jun 2017
56-day deadline 4 Oct 2017 est.
Responses identified 0 of 1
Product related deaths

Coroner's concerns

AI summary
The lack of purchase limits for loperamide medication at retail stores enables bulk buying, increasing the risk of addiction and overdose.
View full coroner's concerns
_ Mr McCaffrey's ex-partner gave evidence that Mr McCaffrey would regularly purchase large quantities of loperamide medication: Following the incident on the 13 January 2017 , she counted 250 tablets that had been taken (the empty packets were in the back-pack in his possession): The receipts were also present within the bag: She advised that he had purchased large amounts of this medication from a budget store as well as smaller quantities from a supermarket and a chemist. It was clear that Mr McCaffrey would frequently large amounts of this medication from a single store. The concern is that there is no apparent Iimit on the amount of loperamide medication that can be purchased from a single store. This makes the medication easier to purchase in large quantities_ am concerned that action should be taken to limit the amount of loperamide medication that can be purchased from a single store, due to the fact that it is apparently used (on occasion) t0 fuel addiction and to the risk of overdose and death

Report sections

Investigation and inquest
On the 20lh January 2017 an investigation was commenced into the death of Aaron John Peter McCaffrey: An inquest was opened on the 20lh January 2017 and concluded on 31s May 2017 . The medical cause of death was: Ia Hypoxic brain injury Multiple cardiac arrests Loperamide overdose The Coroner's Conclusion was: "drug-related" death:
Circumstances of the death
Mr McCaffrey had a history of taking large quantities of loperamide medication_ This Is a medication that is available "over-the-counter" and is often referred to under the brand name 'Imodium" Mr McCaffrey had a history of addiction lo opiate medications, which dated back a number of years This included addiction t0 medicalions such as CO-codamol: However, he later developed an addiction to loperamide medication and _ in the years prior to his death he was known to regularly take in the region of 150 tablets per day: Mr McCaffrey's ex-partner explained in evidence that this was the amount that Mr McCaffrey would admit to taking but she suspected that he took more than this on occasion; It was clear that the history of addiction was part of the reason for the relationship breakdown, althoughE remained in close contact with Mr McCafirey: as they had young children together: Loperamide medication contains a low level of opiate. Mr McCaffrey was known t0 suffer from anxiety, although he kept any mental health concerns mainly to himself. He told that he took large amounts of loperamide medication because it made him feel better On the 13th January 2017 Mr McCaffrey took in the region of 250 loperamide tablets: He collapsed in the toilets at the Tesco Store in Droylsdon, Manchester and was taken by ambulance to Tameside General Hospital His condition deteriorated in hospital (despite medical treatment) and he died on the 19" January 2017. The Conclusion was recorded as: "drug-related death" Mr McCaffrey did not intent to end his own life. His death was an unintended consequence of consuming the large amount of loperamide medication the
Action should be taken
In my opinion action should be taken to prevent future deaths and believe you have the power t0 take such action.

Similar PFD reports

Shared signals

Report details

Reference
2017-0195
Date of report
16 June 2017
Coroner
Rachel Galloway
Coroner area
Manchester (South)

Responses identified

Responses identified 0 of 1
1 response not yet linked

Organisations named in PFD reports are normally expected to respond within 56 days. Deadline: 4 Oct 2017 (estimated).

Sent to

Medicines and Healthcare products Regulatory Agency

Source links